Delivery Order SPE2DB20D2014-SPE2DB25FD02B
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,689.24 to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 16, 2025, and performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction within AmerisourceBergen's broader federal pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $3,633.25 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract utilizes a firm fixed price arrangement with an ultimate completion date of August 8, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will occur at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $37,730.25. This competitively awarded, firm fixed-price delivery order is set to be completed by August 20, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $3,786.99 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $5,670.68 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials, with a completion date of August 19, 2025. The contract utilizes firm fixed pricing and carries no set-aside designation, indicating it was awarded through open competition. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,946.80 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml quantities. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's competitive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a ceiling value of $1,957.32. This competitive, firm fixed-price delivery order is set to be completed by August 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under a larger contract vehicle, reflecting the company's role as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $3,759.96. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 27, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a small-value transaction typical of the company's regular medical supply deliveries...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a contract ceiling value of $5,010.26. This is a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $18,687.41 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to meet federal procurement...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FD02BDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $25,754.62 to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials. The contract is a firm fixed price delivery order with a completion date of September 17, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal procurement requirements for pharmaceutical products. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medical products to support military healthcare systems and other federal agencies, including the Defense Health Agency and U.S. Coast Guard. The company's portfolio encompasses brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains, positioning it as a critical vendor within the DLA's global pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.8k | 9/16/25 |